Drug Profile
Bupivacaine extended release - Pacira BioSciences
Alternative Names: Bupivacaine extended-release - Pacira BioSciences; Bupivacaine extended-release liposome injection; Bupivacaine liposome extended-release injectable suspension; Bupivacaine liposome injectable suspension; DepoBupivacaine; Exparel; SKY-0402Latest Information Update: 21 Feb 2024
Price :
$50
*
At a glance
- Originator SkyePharma Inc
- Developer Nuance Biotech; Pacira BioSciences; Pacira Pharmaceuticals
- Class Analgesics; Anilides; Anti-inflammatories; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Piperidines; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Anaesthesia; Postoperative pain
- Phase III Dental pain
- No development reported Musculoskeletal pain; Pain
Most Recent Events
- 16 Feb 2024 Efficacy and adverse events data from a phase III STRIDE trial in Postoperative pain released by Pacira Pharmaceuticals
- 31 Dec 2023 Pacira BioSciences has patent protection for EXPAREL® in USA, Europe, China, Israel and Japan
- 31 Dec 2023 Pacira BioSciences plans to commercialise Exparel® for Postoperative pain (In adolescents, In children)